20-F: Belite Bio's Tinlarebant Phase 3 Success, NDA Planned

Belite Bio announces highly significant Phase 3 DRAGON trial results for tinlarebant in STGD1, with an FDA NDA submission expected in Q2 2026, alongside ongoing GA trials and substantial capital raises.

Summary

• Belite Bio is a clinical-stage biopharmaceutical company focused on degenerative retinal diseases, specifically Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA), and metabolic diseases including NAFLD, NASH, T2D, and gout.
• The lead product candidate, tinlarebant (LBS-008), is an orally administered, once-a-day tablet for STGD1 and GA, addressing unmet medical needs as there are no FDA-approved treatments for STGD1 and no approved orally administered treatments for GA.
• The Phase 3 DRAGON trial for adolescent STGD1 patients achieved its primary endpoint, demonstrating a highly statistically significant 35.7% reduction in the annualized macular lesion growth rate (p=0.0033) compared to placebo over a 2-year treatment period.
• Tinlarebant was well tolerated in the DRAGON trial, with most drug-related ocular adverse events (xanthopsia, delayed dark adaptation, night vision impairment) reported as mild and resolving during the trial; headaches were the most common non-ocular adverse event.
• An NDA submission to the FDA for tinlarebant in STGD1 is expected in the second quarter of 2026.
• The Phase 3 PHOENIX trial for GA associated with dry AMD has completed patient enrollment with a total of 530 subjects across the U.S., UK, France, Czech Republic, Switzerland, China, Taiwan, and Australia.
• Tinlarebant has received multiple expedited regulatory designations for STGD1, including Orphan Drug Designation in the US, Europe, and Japan, Rare Pediatric Disease Designation in the US, Fast Track designation in the US, and Sakigake (Pioneer Drug) Designation in Japan.
• The company reported a net loss of US$77.6 million for the year ended December 31, 2025, an increase from US$36.1 million in 2024.
• Net cash used in operating activities increased to US$40.7 million for 2025, up from US$29.2 million in 2024.
• Research and development expenses increased by 51.6% to US$45.4 million in 2025, primarily driven by the PHOENIX trial, share-based compensation, and Active Pharmaceutical Ingredient (API) manufacturing expenses.
• Selling, general and administrative expenses increased by 286.1% to US$38.8 million in 2025, mainly due to a significant increase in share-based compensation expenses (US$24.6 million) and professional service fees.
• As of December 31, 2025, the company held US$352.9 million in cash and cash equivalents and US$419.7 million in held-to-maturity investments (US Treasury bills and notes).
• Net cash provided by financing activities was US$663.2 million in 2025, primarily from a US$350.0 million underwritten public offering, a US$125.0 million PIPE offering, and US$103.0 million from warrant exercises.
• The company believes its current cash and cash equivalents, combined with proceeds from public offerings and private placements, will be sufficient to meet its general corporate purposes for at least the next 12 months.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development due to the successful Phase 3 trial results for tinlarebant in STGD1, which significantly de-risks the lead asset and paves the way for an NDA submission. The strong financial position from recent capital raises further supports ongoing development and future commercialization efforts, despite continued operating losses.

Positives

• Tinlarebant's Phase 3 DRAGON trial for adolescent STGD1 patients achieved its primary endpoint with a highly statistically significant 35.7% reduction in annualized macular lesion growth rate (p=0.0033) compared to placebo.
• Tinlarebant demonstrated a favorable safety profile in the DRAGON trial, with most drug-related ocular adverse events reported as mild and resolving.
• An NDA submission to the FDA for tinlarebant in STGD1 is expected in Q2 2026, indicating clear progress towards potential market approval.
• Tinlarebant has received multiple expedited regulatory designations for STGD1, including Orphan Drug Designation (US, EU, Japan), Rare Pediatric Disease Designation (US), Fast Track designation (US), and Sakigake (Pioneer Drug) Designation (Japan), which could accelerate development and review.
• The Phase 3 PHOENIX trial for Geographic Atrophy (GA) has completed patient enrollment with 530 subjects, advancing another key product candidate.
• The company successfully raised substantial capital in 2025, including a US$350.0 million underwritten public offering and a US$125.0 million PIPE offering, significantly strengthening its financial position.
• Cash and cash equivalents increased to US$352.9 million as of December 31, 2025, from US$31.7 million in 2024, providing a strong liquidity position.
• The company's RBP4 IP Portfolio includes 27 issued U.S. patents and 25 issued foreign patents, offering robust intellectual property protection for its lead candidates.
• The mechanism of RBP4 inhibition, central to tinlarebant, has been recognized and recommended as a priority for clinical development in STGD1 and dry AMD by the U.K. National Institute for Health Research.

Negatives

• The company has incurred significant and increasing net operating losses, reaching US$77.6 million in 2025, up from US$36.1 million in 2024.
• Net cash used in operating activities increased to US$40.7 million in 2025 from US$29.2 million in 2024, indicating a continued high cash burn rate.
• The company has a limited operating history and no history of commercializing pharmaceutical products, which makes evaluating future viability challenging.
• Significant reliance on third-party Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) introduces risks related to performance, compliance, and meeting deadlines.
• The company expects to continue incurring significant operating losses for the foreseeable future.
• The market price of the company's ADSs has experienced high volatility, with a range from US$8.87 to US$190.30 since listing.
• Extensive and evolving regulatory requirements in multiple jurisdictions (US, EU, China, Japan) are time-consuming and costly, posing ongoing compliance burdens.
• Limited insurance coverage means claims beyond current coverage could result in substantial costs and diversion of resources.
• Exposure to foreign exchange risks due to international operations and clinical trials can impact financial results.
• Changes in U.S. and Chinese government policies, including potential intervention, trade restrictions, or increased oversight, could adversely affect business, capital raising, and ADS value.
• The company expects to be classified as a Passive Foreign Investment Company (PFIC) for 2025 and the current taxable year, which could lead to adverse U.S. federal income tax consequences for U.S. investors.
• Loss of 'emerging growth company' status results in increased compliance costs and more extensive reporting requirements.
• No expectation of paying dividends in the foreseeable future, requiring investors to rely solely on stock price appreciation for returns.

Risks

• Business is highly dependent on the success of tinlarebant (LBS-008); failure to develop, obtain marketing approval, or successfully commercialize it would cause significant harm.
• All product candidates are in clinical or preclinical development; inability to complete clinical development and obtain regulatory approval, or significant delays, would materially harm the business.
• Need to obtain substantial additional financing to fund operations; inability to secure such financing may prevent completion of product development and commercialization.
• Limited operating history and no history of commercializing pharmaceutical products make it difficult to evaluate future viability.
• Regulatory approval processes are time-consuming, expensive, and uncertain, and may evolve over time, potentially delaying or denying approval.
• Product candidates may cause serious adverse side effects or prove less effective than anticipated, leading to delays, denial of approval, or negative consequences post-approval.
• Results of earlier preclinical studies and clinical trials may not be predictive of future study results, and failure can occur at any stage.
• Delays or difficulties in enrolling and retaining patients in clinical trials could adversely affect clinical development progress and regulatory approvals.
• Manufacture of biopharmaceutical products is complex and relies on third-party CMOs; problems could lead to significant delays, increased costs, or inability to obtain regulatory approval.
• Inability to obtain and maintain patent and other intellectual property protection, or if the scope is not sufficiently broad, third parties could commercialize competitive products.
• Dependence on intellectual property licensed from third parties; failure to comply with license obligations, termination of licenses, or disputes could lead to loss of significant rights.
• Future success depends on the ability to attract, retain, and motivate senior management and qualified employees.
• Market opportunities for product candidates, if approved, may be smaller than anticipated due to reliance on estimates and third-party sources for patient population data.
• Product liability lawsuits could divert resources, cause substantial liabilities, and limit commercialization of any approved products.
• Illegal and/or parallel imports and counterfeit pharmaceutical products may reduce demand for future approved product candidates and harm reputation.
• Ability to use net operating loss carryforwards may be subject to limitations by tax rules.
• Raising additional capital may cause dilution to shareholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• Ongoing regulatory obligations and continued regulatory review post-approval may result in significant additional expenses and penalties for non-compliance.
• Inadequate funding for and other disruptions at the FDA and other government agencies could hinder their ability to review and process regulatory submissions in a timely manner.
• Current and future legislation (e.g., ACA, IRA, state-level pricing controls) may increase the difficulty and cost of obtaining marketing approval and commercializing product candidates, and affect pricing.
• Changes in patent laws or their interpretation could diminish the value of patents in general, impairing the ability to protect product candidates.
• Inability to protect the confidentiality of trade secrets would harm business and competitive position.
• Claims challenging the inventorship of patents and other intellectual property.
• Intellectual property litigation may lead to unfavorable publicity, harm reputation, cause ADS price decline, and limit research and development activities or commercialization ability.
• Failure to identify relevant third-party patents or incorrect interpretation of their relevance, scope, or expiration.
• Claims that product candidates or their sale/use infringe, misappropriate, or otherwise violate third-party intellectual property rights could result in costly litigation or require substantial time and money to resolve.
• Issued patents covering product candidates could be found invalid or unenforceable if challenged in court.
• May not be successful in obtaining or maintaining necessary rights for the development pipeline through acquisitions and in-licenses.
• If trademarks and trade names are not adequately protected, the ability to build name recognition and competitive position may be adversely affected.
• Intellectual property rights do not necessarily protect against all potential threats to competitive advantage.
• Failure to implement and maintain an effective system of internal controls could lead to inaccurate reporting, failure to meet reporting obligations, or fraud.
• Difficulties in managing growth as the organization increases in size and capabilities.
• Disruptions in the financial markets and economic conditions could affect the ability to raise capital.
• Failure to renew current leases or locate desirable alternatives for leased properties could materially and adversely affect the business.
• Future acquisitions or strategic collaborations may increase capital requirements, dilute investment, cause debt, or assume contingent liabilities.
• Tax laws of the jurisdictions in which the company operates are subject to change and uncertain interpretation, potentially affecting business and tax results.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or penalties.
• Internal computer systems, or those used by CROs or other contractors, may fail or suffer security breaches, disrupting development.
• Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, private litigation, and adverse publicity.
• Business disruptions from natural disasters, acts of war or terrorism, or other factors beyond control could seriously harm future revenue and financial condition.
• Subject to changing laws and regulations regarding regulatory matters, corporate governance, and public disclosure, increasing costs and risk of non-compliance.
• Granting options and other equity awards under incentive plans may result in increased share-based compensation expenses and dilution to existing shareholders.
• Failure to comply with certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations could lead to serious consequences.
• Exposure to foreign exchange risks due to international operations and expenses denominated in local currencies.
• Changes in the political and economic policies of the Chinese government or in relations between China and the United States may materially and adversely affect business and ADS price.
• The Chinese government may intervene in or influence operations at any time, potentially impacting the value of ADSs.
• Subject to changing legal and regulatory requirements in the PRC pharmaceutical industry, with new laws potentially affecting profitability or imposing additional compliance burdens.
• May be restricted from transferring scientific data out of the PRC due to evolving regulations.
• Uncertainty of patent linkage, patent term extension, and data and market exclusivity for NMPA-approved pharmaceutical products in China could increase the risk of early generic competition.
• Loss of foreign private issuer status in the future could result in significant additional costs and expenses.
• As an exempted company incorporated in the Cayman Islands, the company is permitted to adopt certain home country corporate governance practices that differ from Nasdaq standards, potentially affording less protection to shareholders.
• Holders of ADSs have fewer rights than shareholders and limited voting rights by the terms of the deposit agreement.
• The depositary for the ADSs is entitled to charge holders of ADSs fees for various services.
• Right to participate in any future rights offerings may be limited, which may cause dilution to holdings.
• May not receive cash dividends if the depositary decides it is impractical to make them available.
• Limitations on transfer of ADSs.
• Certain judgments obtained against the company by shareholders may not be enforceable in the Cayman Islands.
• ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement.
• Memorandum and articles of association contain anti-takeover provisions that could have a material adverse effect on the rights of holders of ordinary shares and ADSs.
• Techniques employed by short sellers may drive down the market price of ADSs.

Future Outlook

The company expects to submit an NDA to the FDA for tinlarebant in STGD1 in the second quarter of 2026. It anticipates continued significant and increasing net operating losses for at least the next several years as it advances tinlarebant, develops other product candidates, and potentially initiates new pipelines. Research and development expenses and selling, general and administrative expenses are projected to increase. The company believes its current cash and cash equivalents, along with proceeds from recent public offerings and private placements, will be sufficient to meet its general corporate purposes for at least the next 12 months, but may require further funding. Future operations are expected to be funded in part by product sales or out-licensing/collaboration agreements, if successful.

Management Comments

• We believe the granting of share-based compensation is of significant importance to our ability to attract and retain key personnel and employees, and we will continue to grant share-based compensation to employees in the future.
• We believe that our current facilities are sufficient to meet our near-term needs, and we do not foresee any difficulty in extending the lease terms of our facilities upon their respective expiration dates.
• We believe that our cash and cash equivalents, together with our cash generated from our public offerings and private placements, will be sufficient to meet our current and anticipated needs for general corporate purposes for at least the next 12 months.
• We believe our supplier has sufficient capacity to meet our demands for drug materials. In addition, we believe that adequate alternative sources for such supplies exist.
• We believe that our core competencies in the identification, research and development of innovative therapies and our management teams regulatory and commercialization expertise provide us with distinct competitive advantages.

Industry Context

StockSavvy.ai notes that Belite Bio's focus on RBP4 inhibition for STGD1 and GA aligns with a recognized priority for clinical development in these degenerative retinal diseases, as highlighted by the U.K. National Institute for Health Research. The successful Phase 3 DRAGON trial results for tinlarebant position the company favorably in the competitive landscape, especially given the current lack of FDA-approved oral treatments for GA and any approved treatments for STGD1. The company's strategy to target adolescent STGD1 patients first, with the potential to expand to the larger adult population, is a common and effective approach in rare disease drug development. The substantial capital raises in 2025 reflect investor confidence in the company's pipeline and strategic direction, particularly in a high-risk, high-reward biopharmaceutical sector.

Comparison to Industry Standards

• Tinlarebant's 35.7% reduction in annualized macular lesion growth rate in the Phase 3 DRAGON trial for STGD1 is compared to historical control data from the ProgStar natural history study, showing a sustained lower DDAF lesion growth (p<0.001) in tinlarebant-treated subjects, indicating a clinically meaningful benefit against a natural progression benchmark.
• The company highlights that tinlarebant's Phase 3 STGD1 clinical study is the only completed Phase 3 trial for STGD1, with one other company currently conducting an ongoing Phase 3 trial, suggesting a potential first-to-market advantage if approved.
• In Geographic Atrophy (GA), Belite Bio notes five other companies advancing treatments, with three in Phase 3 development and two having completed Phase 3 and received FDA approval for *intravitreally injected* therapeutic agents. Tinlarebant, if approved, would be a *novel oral therapeutic*, differentiating it from existing approved treatments in GA.
• The company's confidence in RBP4 reduction as a viable treatment is supported by findings from a 2-year Phase 2 proof-of-concept study of fenretinide in dry AMD patients with GA, where a subset achieving >70% RBP4 reduction showed a mean reduction of 0.33 mm² in yearly lesion growth rate compared to placebo (1.70 mm²/year vs. 2.03 mm²/year). Tinlarebant has demonstrated a sustained mean RBP4 reduction of over 70% in its Phase 1b STGD1 trial, suggesting it meets this therapeutic threshold more consistently.
• The safety profile of long-term RBP4 inhibition is referenced against a 5-year fenretinide trial, which showed generally mild and reversible adverse events (DDA, dermatologic disorders) and a low discontinuation rate (4.4%), providing a benchmark for tolerability.

Management Changes

Corporate Governance

Legal Proceedings

• Currently not involved in any legal or administrative proceedings that may have a material adverse impact on the business, financial position, or results of operations.

Related Party Transactions

• Lin BioScience, Inc. (parent company of the largest shareholder) provided new drug development services for tinlarebant to the company, with expenses of US$37 thousand in 2025 (US$63 thousand in 2023, US$57 thousand in 2024).
• The company provided new drug development services for LBS-007 (Lin BioScience, Inc.'s cancer pipeline) to Lin BioScience, Inc., with no reimbursement received in 2025 (US$46 thousand in 2023, nil in 2024).
• As of December 31, 2025, US$5 thousand was due to Lin BioScience, Inc.
• The largest shareholder, Lin Bioscience International Ltd., beneficially owned approximately 42.8% of outstanding ordinary shares as of the Latest Practicable Date, enabling substantial influence over corporate matters.
• Executive officers Yu-Hsin Lin (CEO), Hao-Yuan Chuang (CFO), Nathan L. Mata (CSO), and director Wan-Shan Chen entered into Rule 10b5-1 Plans in December 2025 for the potential sale of shares.

Stakeholder Impact

• **Shareholders**: Potential for significant returns if tinlarebant is successfully commercialized, but also risk of dilution from future capital raises and volatility in ADS price. ADS holders have limited voting rights compared to direct shareholders. U.S. investors may face adverse U.S. federal income tax consequences if the company is classified as a PFIC.
• **Patients (STGD1 & GA)**: Potential for a novel oral therapeutic (tinlarebant) to slow disease progression and vision loss, addressing significant unmet medical needs in these conditions.
• **Employees**: Share-based compensation plans are used to attract and retain key personnel. The company's anticipated growth will require hiring additional qualified personnel, particularly in R&D, regulatory affairs, and business development.
• **Columbia University**: Receives license fees, milestone payments (US$4 million paid to date, US$6 million expected in the near term), and single-digit earned royalties on net sales of licensed products, as well as a percentage of revenue from any priority review voucher sale.
• **Third-party CROs/CMOs**: Continued reliance on these organizations for preclinical, clinical, and manufacturing activities provides ongoing business opportunities for these partners.
• **Regulatory Authorities**: Ongoing engagement with regulatory bodies (FDA, EMA, NMPA, PMDA, TGA) for approvals and compliance, with potential for delays or additional requirements impacting development timelines.

Next Steps

• Submit an NDA to the FDA for tinlarebant in STGD1 in the second quarter of 2026.
• Continue the Phase 2/3 DRAGON II clinical trial of tinlarebant in adolescent STGD1 patients in Japan, the United States, and the United Kingdom.
• Continue the Phase 3 PHOENIX trial for GA associated with dry AMD.
• Conduct an interim analysis for the PHOENIX trial.
• Advance LBS-009 through preclinical development for NAFLD, NASH, and T2D.
• Identify and develop additional product candidates and/or for additional indications using the RBP4 IP Portfolio.
• Further expand the product pipeline through in-licensing or collaboration arrangements.
• Establish sales, marketing, distribution, and other commercial infrastructure for approved products.
• Obtain, maintain, expand, and protect the intellectual property portfolio.
• Hire and retain additional personnel, including clinical, scientific, and commercialization staff.
• Add operational, financial, and management information systems and personnel to support product development and public company obligations.
• Add equipment and physical infrastructure to support research and development.
• Make additional payments of US$6 million to Columbia University upon near-term expected completion of development milestones.

Key Dates

Recommendation

The highly statistically significant positive Phase 3 DRAGON trial results for tinlarebant in STGD1 represent a major de-risking event for Belite Bio's lead product candidate, positioning it for an NDA submission in Q2 2026. This success, coupled with Breakthrough Therapy and other expedited designations, suggests a strong potential for market approval in an area with no current FDA-approved treatments. The company's robust cash position, bolstered by recent substantial capital raises, provides ample runway to advance its pipeline and pursue commercialization. While the company faces ongoing losses and regulatory complexities, the clinical validation of its lead asset and strategic financial strength make it a compelling investment for long-term growth in the biopharmaceutical sector.

Keywords

Biopharmaceutical, Stargardt disease, Geographic Atrophy, AMD, Tinlarebant, LBS-008, Clinical trials, Phase 3, Drug development, Orphan drug, Rare pediatric disease, RBP4 antagonist, SEC filing, Nasdaq, Biotechnology, Pharmaceutical, Capital raise, Financial results, Corporate governance, Intellectual property, Regulatory approval, Metabolic diseases, NAFLD, NASH, Type 2 Diabetes, LBS-009